Pathology and pathophysiology of inhalational anthrax in a Guinea pig model

Infection and Immunity

Volumn 81, Issue 4, 2013, Pages 1152-1163

  Savransky, Vladimir ^a   Sanford, Daniel C ^b   Syar, Emily ^b   Austin, Jamie L ^b   Tordoff, Kevin P ^b   Anderson, Michael S ^b   Stark, Gregory V ^b   Barnewall, Roy E ^b   Briscoe, Crystal M ^b   Lemiale Biérinx, Laurence ^a   Park, Sukjoon ^a   Ionin, Boris ^a   Skiadopoulos, Mario H ^a  

^a Emergent Biosolutions   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; EDEMA; FEMALE; GUINEA PIG; HISTOPATHOLOGY; LD 50; LUNG; LYMPHOCYTE DEPLETION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; LETHAL DOSE 50; MALE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84875552895     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01289-12     Document Type: Article

References (67)

1. Brachman PS. 1980. Inhalation anthrax. Ann. N. Y. Acad. Sci. 353:83-93.
2. Penn CC, Klotz SA. 1997. Anthrax pneumonia. Semin. Respir. Infect. 12:28-30
3. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. 1999. Inhalational anthrax: epidemiology, diagnosis, and management. Chest 116: 1369-1376.
4. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. 2006. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann. Intern. Med. 144:270-280.
5. Golden HB, Watson LE, Lal H, Verma SK, Foster DM, Kuo SR, Sharma A, Frankel A, Dostal DE. 2009. Anthrax toxin: pathologic effects on the cardiovascular system. Front. Biosci. 14:2335-2357.
6. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. 2004. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol. Mol. Biol. Rev. 68:617-629.
7. Goossens PL. 2009. Animal models of human anthrax: the quest for the holy grail. Mol. Aspects Med. 30:467-480.
8. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992.
9. Lawrence WS, Hardcastle JM, Brining DL, Weaver LE, Ponce C, Whorton EB, Peterson JW. 2009. The physiologic responses of Dutch belted rabbits infected with inhalational anthrax. Comp. Med. 59:257-265.
10. Berdjis CC, Gleiser CA, Hartmen HA, Kuehne RW, Gochenour WS. 1962. Pathogenesis of respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 43:515-524.
11. Gleiser CA, Berdjis CC, Hartman HA, Gochenour WS. 1963. Pathology of experimental respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 44:416-426.
12. Henderson DW, Peacock S, Belton FC. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. (Lond.) 54:28-36.
13. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW, Jr, Gibbs PH, Friedlander AM. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
14. Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, Friedlander AM. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Invest. 73:691-702.
15. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, Carnes R, Carney J. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 83:1201-1209.
16. Twenhafel NA, Leffel E, Pitt ML. 2007. Pathology of inhalational anthrax infection in the African green monkey. Vet. Pathol. 44:716-721.
17. Leffel EK, Pitt LM. 2006. Anthrax, p 77-94. In Swearengen JR (ed), Biodefense: research methodology and animal models. CRC Press, Boca Raton, FL.
18. Twenhafel NA. 2010. Pathology of inhalational anthrax animal models. Vet. Pathol. 47:819-830.
19. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. 2001. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11:333-340.
20. Ross JM. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. J. Pathol. Bacteriol. 73:485-494.
21. Ivins BE, Ezzell JW, Jr, Jemski J, Hedlund KW, Ristroph JD, Leppla SH. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infect. Immun. 52:454-458.
22. Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:356-363.
23. Little SF, Knudson GB. 1986. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52:509-512.
24. Lever MS, Stagg AJ, Nelson M, Pearce P, Stevens DJ, Scott EA, Simpson AJ, Fulop MJ. 2008. Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int. J. Exp. Pathol. 89:171-179.
25. Brachman PS, Kaufman AF, Dalldorf FG. 1966. Industrial inhalation anthrax. Bacteriol. Rev. 30:646-659.
26. Dalldorf FG, Kaufmann AF, Brachman PS. 1971. Woolsorters' disease. An experimental model. Arch. Pathol. 92:418-426.
27. Daya M, Nakamura Y. 2005. Pulmonary disease from biological agents: anthrax, plague, Q. fever, and tularemia. Crit. Care Clin. 21:747-763, vii.
28. Guarner J, Zaki SR. 2006. Histopathology and immunohistochemistry in the diagnosis of bioterrorism agents. J. Histochem. Cytochem. 54:3-11.
29. Misra RP. 1991. Manual for the production of anthrax and blackleg vaccines. FAO animal production and health paper 87. Food and Agriculture Organization of the United Nations, Rome, Italy. http://www.fao.org /docrep/004/T0278E/T0278E00.htm.
30. Ivins B, Fellows P, Pitt L, Estep J, Farchaus J, Friedlander A, Gibbs P. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13:1779-1784.
31. Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D. 2002. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect. Immun. 70: 6231-6241.
32. Stephenson EH, Moeller RB, York CG, Young HW. 1988. Nose-only versus whole-body aerosol exposure for induction of upper respiratory infections of laboratory mice. Am. Ind. Hyg. Assoc. J. 49:128-135.
33. Phalen RF, Mannix RC, Drew RT. 1984. Inhalation exposure methodology. Environ. Health Perspect. 56:23-34.
34. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361:135-144.
35. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, et al. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167: 1239-1243.
36. Ravel J, Jiang L, Stanley ST, Wilson MR, Decker RS, Read TD, Worsham P, Keim PS, Salzberg SL, Fraser-Liggett CM, Rasko DA. 2009. The complete genome sequence of Bacillus anthracis Ames "Ancestor". J. Bacteriol. 191:445-446.
37. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. 1999. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:1735-1745.
38. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
39. Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, Kelley MF. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542.
40. Guyton AC. 1947. Measurement of the respiratory volumes of laboratory animals. Am. J. Physiol. 150:70-77.
41. Fieller EC. 1944. A fundamental formula in the statistics of biological assay, and some applications. Q. J. Pharm. Pharmacol. 17:117-123.
42. Finney DJ. 1971. Probit analysis, 3rd ed. Cambridge University Press, New York, NY.
43. Schlesinger RB. 1985. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J. Toxicol. Environ. Health 15:197-214.
44. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
45. Austin JL, Barnewall RE, Sanford DC, Stark GV. 2009. Impact of Bacillus anthracis spore preparation on aerosol performance. Proceedings of Aerobiology in Biodefense III, Cumberland, MD.
46. Austin JL, Guistino DJ, Stark GV, Barnewall RE, Syar ES, Hunt RE. 2009. The impact of storage duration on critical Bacillus anthracis Ames spores characteristics. Proceedings of the 7thASMBiodefense and Emerging Diseases Research Meeting, Baltimore, MD.
47. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 74:1016-1024.
48. Day WC, Bailey RR, TePaske GH, Wallace HC. 1962. Immunological studies with Bacillus anthracis. I. Bacillus anthracis aerosol challenge of guinea pigs vaccinated with protective antigen. U.S. Army Biological Laboratories, Fort Detrick, MD. Technical Memorandum 24. http://www.dtic.mil/dtic/tr/fulltext/u2/285614.pdf.
49. Cieslak TJ, Eitzen EM, Jr. 1999. Clinical and epidemiologic principles of anthrax. Emerg. Infect. Dis. 5:552-555.
50. Wilkening DA. 2006. Sverdlovsk revisited: modeling human inhalation anthrax. Proc. Natl. Acad. Sci. U. S. A. 103:7589-7594.
51. Wilkening DA. 2008. Modeling the incubation period of inhalational anthrax. Med. Decis. Making. 28:593-605.
52. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM, Jr. 1997. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399-411.
53. Franz DR, Jahrling PB, McClain DJ, Hoover DL, Byrne WR, Pavlin JA, Christopher GW, Cieslak TJ, Friedlander AM, Eitzen EM, Jr. 2001. Clinical recognition and management of patients exposed to biological warfare agents. Clin. Lab. Med. 21:435-473.
54. Li Y, Sherer K, Cui X, Eichacker PQ. 2007. New insights into the pathogenesis and treatment of anthrax toxin-induced shock. Expert Opin. Biol. Ther. 7:843-854.
55. Watson LE, Mock J, Lal H, Lu G, Bourdeau RW, Tang WJ, Leppla SH, Dostal DE, Frankel AE. 2007. Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front. Biosci. 12:4670-4675.
56. Lawrence WS, Marshall JR, Zavala DL, Weaver LE, Baze WB, Moen ST, Whorton EB, Gourley RL, Peterson JW. 2011. Hemodynamic effects of anthrax toxins in the rabbit model and the cardiac pathology induced by lethal toxin. Toxins 3:721-736.
57. Rossi CA, Ulrich M, Norris S, Reed DS, Pitt LM, Leffel EK. 2008. Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax. Infect. Immun. 76:5790-5801.
58. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH. 2001. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod. Pathol. 14:482-495.
59. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc. Natl. Acad. Sci. U. S. A. 90:2291-2294.
60. Guarner J, Jernigan JA, Shieh WJ, Tatti K, Flannagan LM, Stephens DS, Popovic T, Ashford DA, Perkins BA, Zaki SR. 2003. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am. J. Pathol. 163:701-709.
61. Lipscomb MF, Hutt J, Lovchik J, Wu T, Lyons CR. 2010. The pathogenesis of acute pulmonary viral and bacterial infections: investigations in animal models. Annu. Rev. Pathol. 5:223-252.
62. Welkos SL, Keener TJ, Gibbs PH. 1986. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51:795-800.
63. Loving CL, Kennett M, Lee GM, Grippe VK, Merkel TJ. 2007. Murine aerosol challenge model of anthrax. Infect. Immun. 75:2689-2698.
64. Ezzell JW, Ivins BE, Leppla SH. 1984. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect. Immun. 45: 761-767.
65. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
66. Baldari CT, Tonello F, Paccani SR, Montecucco C. 2006. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 27:434-440.
67. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shieh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.